Estimating the impact of healthcare-associated infections on length of stay and costs  by De Angelis, G. et al.
Estimating the impact of healthcare-associated infections on length of
stay and costs
G. De Angelis1,2, A. Murthy1,3, J. Beyersmann4 and S. Harbarth1
1) Infection Control Programme, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland, 2) Infectious Diseases Department, Universita`
Cattolica del Sacro Cuore, Rome, Italy, 3) Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA and 4) Institute of Medical Biometry and
Medical Informatics, University Medical Centre Freiburg, Freiburg, Germany
Abstract
Healthcare-associated infections (HAIs) unquestionably have substantial effects on morbidity and mortality. However, quantifying the
exact economic burden attributable to HAIs still remains a challenging issue. Inaccurate estimations may arise from two major sources
of bias. First, factors other than infection may affect patients’ length of stay (LOS) and healthcare utilization. Second, HAI is a time-vary-
ing exposure, as the infection can impact on LOS and costs only after the infection has started. The most frequent mistake in previously
published evidence is the introduction of time-dependent information as time-ﬁxed, on the assumption that the impact of such exposure
on the outcome was already present on admission. Longitudinal and multistate models avoid time-dependent bias and address the time-
dependent complexity of the data. Appropriate statistical methods are important in analysis of excess costs and LOS associated with
HAI, because informed decisions and policy developments may depend on them.
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The Economic Burden of Healthcare-
Associated Infections (HAIs)
Healthcare-associated infections (HAIs) are additional bur-
dens on individual hospitals and healthcare systems [1]. They
can increase the costs of patient care from several economic
perspectives, including those of hospital administrators, third-
party payers and patients. In healthcare systems relying on
ﬁxed per diem accounting systems, the presence of an HAI
does not necessarily decrease reimbursement revenue for
hospitals, as added bed-days can be charged to third-party
payers (e.g. health insurance companies). However, after the
introduction of prospective payment mechanisms based on
diagnosis-related groups and similar classiﬁcations, the
full costs of HAI are most frequently borne by hospitals
themselves. Recently, the decision of the American Centers
for Medicare to stop reimbursement for HAI has increased
the attention paid to this topic and the need for careful
interpretation of surveillance data [2].
Excess costs of HAI are related to additional diagnostic
tests and treatment, additional hospital days, and postdis-
charge complications, among others. Quantifying the exact
economic burden attributable to HAI still remains a challeng-
ing issue [3–5]. Over the last two decades, a number of
studies with different designs have attempted to estimate the
excess burden of HAI [6,7]. Earlier data from the UK pro-
vide a telling picture. Some individual Trusts within the
National Health System have attempted to estimate the
costs of individual outbreaks of speciﬁc infections. An out-
break of methicillin-resistant Staphylococcus aureus (MRSA) in
Kettering, for example, was estimated to cost the individual
hospital involved approximately £400 000. [8]. The biggest
cost drivers were those related to the set-up of isolation
wards for infected patients, with other costs mostly being
associated with cleaning and replacement of materials. The
limited knowledge among policy-makers about the true
ﬁnancial burden of HAI, such as MRSA infection, led to a
commissioned study at the London School of Hygiene and
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Tropical Medicine. On the basis of the results of this investi-
gation, HAI was estimated to cost approximately £1 billion
per year, approximately £56 million of which was spent out-
side the hospital by general practitioners and outpatient cen-
tres [9]. Patients with HAI incurred costs that were 2.8
times higher than those for patients free from infection, with
an average incremental cost of approximately £3000. With
respect to length of stay (LOS), patients with HAI spent
approximately 2.5 times more time in hospital, equivalent to
an excess LOS of 11 days. Notably, approximately 19% of
patients in the study showed signs and symptoms of HAI
manifesting after discharge. These postdischarge costs associ-
ated with HAI are likely to have been underestimated, given
the limitations of the available data on outpatient utilization
and indirect costs related to HAI [9].
Since the completion of this landmark study, there have
been several attempts to estimate the excess costs of HAI.
Two systematic reviews of the literature by Stone et al. have
summarized the evidence on this topic between 1990 and
2004; they evaluated a total of 125 studies, 70 of which were
published between 2001 and 2004 [6,7]. This recent increase
in the number of publications highlights the growing interest
in the economic implications of HAI over the last 10 years.
However, these reviews revealed wide variation in the cost
estimates, as well as in the methods used to estimate costs.
Another review of the literature, analysing 45 randomized
controlled trials reporting cost data and covering a wide
variety of clinical areas, reported that only 56% of them gave
results for statistical comparisons between randomized
groups, only 36% gave rational conclusions, and none of
them reported a sample size calculation for cost analyses
[10].
The basic framework used by many of these studies is to
ﬁrst identify the additional time that patients spend in the
hospital as a result of HAI, as well as the speciﬁc healthcare
utilization relating to the treatment and management of the
infection. These additional days and speciﬁc interventions are
then monetized for calculation of the speciﬁc costs attribut-
able to a single infection. Generally, studies that have
followed this basic approach suffer from three limitations.
First, the estimation of healthcare utilization, and more spe-
ciﬁcally LOS in hospital, that can be attributed to HAI is
often biased. Several factors other than infection may be
associated with patients’ excess LOS and healthcare utiliza-
tion. Second, the approaches used to measure the costs of
healthcare resource use are often biased when researchers
fail to account for important differences between true costs,
charges and reimbursement levels, for example. In addition,
ﬁnancial accounting systems may not always allow for appro-
priate identiﬁcation of ﬁxed and variable costs, leading to
inaccurate estimates. Third, many studies on the excess costs
of HAI are not explicit in their selection of a cost perspec-
tive, and may not include appropriate cost measures. For
example, a comprehensive approach to estimating costs from
the hospital perspective would explore the costs associated
with foregone revenue when infected patients occupy beds
for longer periods of time [3].
One of the main drivers of hospital costs attributable to
HAI is the associated excess LOS of a patient in hospital.
Quantifying excess hospital stay is essential for assessing how
many bed-days might be gained from prevention [3,11]. If an
HAI in a given patient is prevented, it is expected that the
total cost for this patient will decrease through the elimina-
tion of variable costs associated with treating the infection
and ﬁxed costs associated with excess LOS resulting from
the infection. However, the hospital may not realize actual
economic savings. This is dependent on the distribution of
total costs between ﬁxed and variable costs. Expenditures
associated with infection that can be avoided, resulting in
actual ‘cash’ savings to the hospital, are generally referred to
as ‘variable’, because they increase or decrease as patient
volume increases and decreases. Examples of variable costs
include drugs and consumables. However, many expenditures
cannot be easily terminated when infections are avoided.
These expenditures are generally referred to as ‘ﬁxed’, and
may include capital equipment, buildings, and staff who are
employed on a long-term or permanent basis. When infec-
tion is avoided, these ‘ﬁxed’ costs cannot quickly be elimi-
nated. As the majority of hospital costs are ﬁxed and not
avoidable in the short term, these costs are the ones that
are most relevant for economic analysis. Although these
costs cannot be avoided to produce ‘cash’ savings, they do
represent signiﬁcant consumption of resources that could be
targeted to other productive areas. Consequently, interpre-
tation of cost savings resulting from the prevention of HAI
should not be as cash savings, but instead as resources that
are freed up for application to other revenue-generating
activities. Only with this strict deﬁnition can the costs be
viewed as those associated with infection. However, for the
purposes of economic evaluation, a short-term perspective
that examines the alternative uses of the ﬁxed costs, and the
corresponding gains and losses of these alternative uses, is
more relevant. In particular, ﬁxed costs made available
through prevention of HAI (e.g. bed-days) can be re-allo-
cated to the treatment of more patients, thereby generating
additional beneﬁts (revenue) for the hospital along with addi-
tional (variable) costs for each new case. The net beneﬁt of
these additional cases represents the opportunity costs of
infection, and more closely reﬂects the short-term costs (or
potential savings with successful intervention) that are
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relevant for hospital administrator decision-making regarding
investments in infection control [3].
Assessing Excess LOS Associated with HAI:
Quality and Limitations of the Available
Evidence
As outlined above, cost analyses of HAI pose an important
concern for accuracy. This is partly but crucially explained
by the assessment of excess LOS associated with HAI,
which represents an important and underestimated method-
ological challenge [12–16]. Inaccurate estimations may arise
from two major sources of bias. First, the time-dependent
nature of HAI implies that infection can impact on LOS and
costs only after the infection has started. Time-ﬁxed studies
that include time-varying exposures as artiﬁcially ﬁxed in
time generate a type of bias called ‘time-dependent’, which
overstates the prolonging effect of the exposure on LOS
[17]. Second, factors other than infection may affect
patients’ LOS and healthcare utilization. These factors may
themselves increase the risk of infection, and may vary with
time [16]. Omission of these confounders, such as patient’s
comorbidities or daily severity of illness, in the estimation
of extra LOS has the potential to produce misleading
results [13,16].
Matching design, linear regression models and instrumental
variables
When assessing the impact of HAI on outcomes such as
extra LOS and costs, the ﬁrst challenge is to tease out the
independent effect of infection on the outcome by making
allowances for all observable confounders. Comparative
cohort studies, using either a matching design in which
patients with HAI are matched to one or more control
patients who did not experience the infection [18–22], or
multivariable statistical regression analyses, which may avoid
the selection bias induced by the matching process and may
allow for the control of a larger number of confounders
[13,23,24], are commonly preferred to overcome this bias.
Although the use of these statistical techniques is a signiﬁcant
step forwards, there remains the potential for bias through
the omission of variables, especially given the paucity of
well-designed studies that can shed light on all potential con-
founders of healthcare utilization. As a result, the number of
independent explanatory variables should be signiﬁcantly
expanded to reduce the risk of confounding and increase
the accuracy of the estimate. In an extreme example,
Graves et al. [13] included up to 123 possible confounding
variables in an analysis of the effect of nosocomial infec-
tions on LOS, minimizing bias resulting from omitted
variables.
More recent techniques for the use of regression models
have raised the potential for endogeneity bias. This source of
bias arises from the reverse causality between risk of HAI
and LOS in hospital. In fact, the direction of causality
between HAI and LOS is not one-way. This bias results from
the interaction between time in hospital and risk of HAI, as
a key driver of costs is the additional LOS associated with
the infection, but the risk of developing an infection is
increased every day that a patient stays longer in the hospital
[25–27]. For instance, the longer the patient is hospitalized,
the greater the opportunity for the patient to experience
the use of invasive medical devices that may cause HAI, and
the higher the cumulative probability of occurrence of a
nosocomial infection.
A two-stage instrumental variable strategy has been pro-
posed for controlling bias from endogenous variables. Instru-
mental variables are ‘variables which are strongly correlated
with the endogenous variable, but uncorrelated with the main
outcome variable, once other covariates have been con-
trolled for. Instrumental variables act as a kind of randomizing
device, identifying a portion of the endogenous variable that
is beyond the control of the individual’ [28]. In other words,
this approach relies on the identiﬁcation of an instrumental
variable that is correlated with the exposure term (HAI) in
the model but is not endogenous, or an independent predic-
tor of LOS. Generally, the stronger the relationship between
the instrument and the exposure, the more precise will be
the estimate of the outcome [29]. The appropriate modelling
of endogenous predictor variables is a critical challenge with
this analytical method. Using data previously collected by
Plowman et al. [30] on 899 patients from a district general
hospital in the UK, Graves et al. [31] used a two-stage instru-
mental variable estimation strategy to overcome the bias
from endogenous variables to estimate the costs associated
with lower respiratory tract infections. On the basis of the
results of the regression analysis, the authors tested the pres-
ence of nasogastric tube and oxygen therapy as instruments,
because of the evidence that both were risk factors for the
development of HAI, but neither of them was a determinant
of LOS. The model predicted that for every 10% decrease in
the probability of acquiring a lower respiratory tract infec-
tion, the expected costs will fall by £693 [31].
Matched-cohort studies remain the most commonly used
method for estimating LOS and costs associated with HAI,
and produce heterogeneous results [32]. Such studies
‘match’ controls to account for factors unrelated to HAI that
may inﬂuence hospital utilization and resource use. Thus,
infected and uninfected patients are usually matched for
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patient demographic data, indicators of disease severity, and
factors relating to hospital admission, as well as additional
variables that may have contributed to excess morbidity and
LOS [33,34]. However, the matching factors used in various
studies have varied, as have the types of infection investi-
gated, suggesting that the identiﬁcation of appropriate match-
ing factors for speciﬁc HAIs may not be straightforward.
Vrijens et al. [22] recently used a matched-cohort study to
estimate the effect of hospital-acquired bloodstream infection
on LOS and costs in 1839 patients from 19 acute hospitals
in Belgium, and investigated the inﬂuence of the choice of
different matching factors on the estimates. Authors showed
that the more matching variables included, the smaller the
increase in LOS and cost. The most critical factor inﬂuencing
the ﬁnal estimate was the time preceding the infection. After
inclusion of this matching factor, the estimation of additional
LOS dropped from 21 to 7 days. Nevertheless, the matching
process may suffer from important sources of bias. A key
issue is the selection bias arising from the number of match-
ing variables used to control for confounding [32]. For
instance, the most accurate estimate in the matched study
by Vrijens et al. [22] relied upon only a selected sample
(50%) of patients initially included in the analysis.
Longitudinal and multistate models
Analytical techniques that account for variation in time at
risk are particularly valuable when exposures change over
time. In outcome studies in which the aim is to estimate the
effect of HAI on endpoints such as LOS or costs, HAI is a
time-varying exposure. Infected patients are deemed to be
exposed after onset of infection, and the interval from start
of follow-up to onset of HAI differs from patient to patient.
Prior to this, patients are unexposed, as are patients who
never experience an infection.
When the time at risk varies substantially from individual
to individual, the incidence rate, denominated by person-time
experience, is the appropriate measure of disease frequency.
This concept is widely understood in infection control, and
forms the basis for measures of disease frequency such as
number of catheter-related infections per 1000 catheter-days
[35]. However, the implications of variation in time at risk
for the choice of an analytical method are less often recog-
nized. The incidence rate is a hazard estimator, assuming the
hazard to be time-constant. However, investigation of LOS
also requires consideration of other hazards, such as the
daily probability of discharge, either with prior infection or
without prior infection. Generally, if there is a need for
adjustment on time at risk, the target parameter of an epide-
miological analysis should be person-time based, usually the
incidence rate ratio or hazard ratio (HR) [36]. Analyses of
data from case–control or cohort studies by logistic regres-
sion often neglect this issue. Sometimes in such analyses, the
time at risk is treated as a conventional risk factor. Although
this approach may be less biased than not accounting for
time at risk at all, it neglects the distinction between time at
risk and other types of confounding [5].
One source of bias occurs when infected and uninfected
patients are compared with regard to total hospital costs or
total hospital LOS. For infected patients, only those days and
costs incurred after the occurrence of the infection are
possibly secondary to infection. The association between
pre-infection outcome and infection is entirely non-causal
from the perspective of measuring the excess burden of
HAI. Therefore, combining pre-infection outcomes with
post-infection outcomes dramatically ampliﬁes confounding,
and overestimates the economic impact of infection [5].
Modifying the analysis such that average post-infection LOS
in infected patients is compared with average total LOS in
non-infected patients does not completely remove confound-
ing by time. Bias persists even in matched-cohort studies in
which non-infected patients are selected to have an LOS at
least as long as the interval to infection in the corresponding
infected patients, irrespective of differences in severity of ill-
ness [37,38]. The reason for this bias is that conditioning on
the presence or absence of HAI induces an association
between the time to infection and time to discharge. In
other words, the matching procedure labels patients as
‘infected’ or ‘uninfected’ before the events ‘HAI’ or ‘dis-
charge without HAI’ occur. In doing this, matching induces a
bias regardless of the matching variables.
Thus, these study designs have several limitations because
of the time-varying nature of the exposure. They do not take
into account the time-dependent nature of nosocomial
infections, but treat HAIs as time-ﬁxed events. These time-
independent (or time-ﬁxed) studies, i.e. outcome analyses
that do not account for the time prior to the occurrence of
nosocomial infection, lead to biased effect estimation, in the
direction of an overestimation of the time to reach the end-
point [12,14,15,17,39–41]. Beyersmann et al. [40], when
studying the effect of nosocomial pneumonia (NP) on LOS,
documented this distortion, showing a difference of end of
LOS HR of 0.65 when NP status was included as a time-
dependent covariate and 0.38 if NP status was treated as
time-ﬁxed, which means that, in both analyses, NP status
prolonged LOS, but in the time-ﬁxed analysis the effect was
overestimated. The biased effect is shown by displaying the
daily end of LOS HRs with and without NP (Fig. 1).
Multistate modelling represents a suitable method to avoid
time-dependent bias, offering a more precise estimation of
extra LOS attributable to HAIs, as well as many other
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cost-consuming in-hospital adverse events [12]. Multistate
models describe several possible events and the transition
between events in a cohort of individuals. Future exposure
status (such as the occurrence of HAI) is considered to be
time-dependent; therefore, individuals move into states at
the times when the events occur, and the composition of
the infected and uninfected groups is subject to change at
any time. The structure of a multistate model can be viewed
as unexposed individuals moving into the exposure state only
when the exposure occurs and into the ﬁnal state when the
study endpoint is observed. In a multistate model assessing
the excess LOS associated with HAI, the occurrence of HAI
would be the time-dependent exposure status, and discharge
and deaths would be the study endpoint (Fig. 2). In addition,
discharge and death can be handled as separate outcomes
[42].
The standard technique used to adjust for confounders is
Cox regression analysis between the transition hazards in
the multistate model. The overall excess LOS, adjusted for
confounders, may then be computed by ﬁrst computing the
‘individual’ excess LOS, i.e. the excess LOS in a population
with identical confounder values, based on the results from
the Cox models. Next, these numbers are averaged over the
study population. This approach is analogous to adjusted
Kaplan–Meier curve estimation [43].
Multistate models also have some limitations. First,
because a multistate model is a representation of events as
they occur over time, individual patient-level data need to be
collected on a daily basis. This might be costly in terms of
labour. Second, multistate models rely on two restricting
assumptions. The ﬁrst assumption is that the probability of
transition into the next state depends only on the current
state. In other words, the future course of a patient (such as
to be discharged or to die) is assumed to depend on the
current HAI status, but not on the time of HAI diagnosis.
The ﬁrst restriction may be relaxed by including the time
since HAI diagnosis in a regression model for the multiple
states. The second assumption concerns the issue that multi-
state models assume that the exact time of the appearance
of HAI is known. The second restriction might be more rele-
vant in clinical trials with periodic follow-up visits of patients
(e.g. every 3 or 6 months) than in a hospital setting, where
daily data records are currently available. Finally, the statisti-
cal analysis might require some sophisticated statistical
expertise and programming.
Typically, survival analysis and multistate models consider
time as a continuous phenomenon, but there are also
approaches that work in a discrete time setting. Recently,
Barnett et al. [16] used a time-discrete multistate model to
quantify the additional LOS spent in an intensive-care unit
associated with MRSA infection. The authors found that
MRSA infection decreased the risk of discharge by 20% with
respect to patients without MRSA infection. They also found
FIG. 1. Illustration of the effect of nosocomial pneumonia (NP) sta-
tus on end of length of stay (LOS) hazard ratios. End of LOS hazard
ratios with and without NP; the x-axis starts with day 5, the ﬁrst
end of LOS day of patients with NP. Solid lines: the unbiased analy-
sis. Dashed lines: the biased analysis. Both analyses ﬁnd that LOS is








FIG. 2. Multistate model describing time-dependent exposure.
Patients are entered into the model on the day of admission to hos-
pital. Patients move into the following states on the day when the
healthcare-associated infection (HAI) and/or discharge and/or death
are detected. Thus, infected patients move from ‘admission’ (state 0)
into ‘HAI’ (state 1), and into ‘discharge’ (state 2) or ‘death’ (state 3);
uninfected patients move from ‘admission’ (state 0) into ‘discharge’
(state 2) or ‘death’ (state 3).
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that the assumption underlying the commonly employed inci-
dence rate, i.e. assuming time-constant daily event probabili-
ties, was not fulﬁlled.
In practice, multistate modelling typically requires daily
individual patient data, as collected in a prospective cohort
study. Key data are the timing of HAI, because LOS before
HAI must not be attributed to HAI, and vital status at the
end of LOS (or at the end of a predeﬁned time period after
hospital stay). Censored data of patients still in hospital by
the end of the study should be also reported properly. The
ﬁrst step is describing the possible state transitions of the
model. This obviously depends on the research question.
Fig. 2, for example, shows the classic model used to analyse
change in LOS attributable to HAI, or in general, an interme-
diate event. The available data, including hospital admission,
HAI and discharge (or death), can be entered in a one-
row-per-subject format (patient-oriented dataset) or in a
transition-oriented format (where each row represents a
transition), using a ‘clock forward’ approach as time-scale;
that is, the times of intermediate (HAI) and ﬁnal (discharge
and death) events refer to the time since the patients
entered the initial state. Describing the statistical analysis of
multistate models is beyond the scope of this review. On
the other hand, some headway has been made in making
these analyses generally available, and statistical packages to
compute excess LOS are freely available online in the
open-source environment R for statistical computing [44,45].
An excellent introduction to multistate models, including a
section on the practical steps, has also been provided by
Andersen et al. [46].
Conclusion
HAIs unquestionably have substantial effects on morbidity
and mortality. However, quantifying the exact economic bur-
den attributable to HAIs still remains a challenging issue. The
matched-cohort study design produces bias in the estimation
of the effects of HAI on LOS and costs. Cost effects or
excess LOS are likely to be overestimated if the interval to
onset of HAI is not properly accounted for in the study
design or analysis. The most frequent mistake in previously
published evidence is the introduction of time-dependent co-
variates as time-ﬁxed, on the assumption that the impact of
such exposure on the outcome remains constant. Longitudi-
nal and multistate models avoid the time-dependent bias
and address the time-dependent complexity of the data.
Appropriate statistical methods are important in the analysis
of excess costs associated with HAI, because informed
decisions and policy developments may depend on them.
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